Literature DB >> 20693870

Taming the ketamine tiger. 1965.

Edward F Domino1.   

Abstract

Pharmacologic actions of CI-581, a chemical derivative of phencyclidine, were determined in 20 volunteers from a prison population. The results indicate that this drug is an effective analgesic and anesthetic agent in doses of 1.0 to 2.0 mg per kilogram. With intravenous administration the onset of action is within 1 min and the effects last for about 5 to 10 min, depending on dosage level and individual variation. No tachyphylaxis was evident on repeat doses. Respiratory depression was slight and transient. Hypertension, tachycardia, and psychic changes are undesirable characteristics of the drug. Whether these can be modified by preanesthetic medication was not determined in this study. Recovery from analgesia and coma usually took place within 10 min, although from electroencephalographic evidence it may be assumed that subjects were not completely normal until after 1 to 2 h. No evidence of liver or kidney toxicity was obtained. CI-581 produces pharmacologic effects similar to those reported for phencyclidine, but of shorter duration. The drug deserves further pharmacologic and clinical trials. It is proposed that the words "dissociative anesthetic" be used to describe the mental state produced by this drug.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20693870     DOI: 10.1097/ALN.0b013e3181ed09a2

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  122 in total

1.  Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.

Authors:  Ji-Woon Kim; Lisa M Monteggia
Journal:  Behav Brain Res       Date:  2019-11-21       Impact factor: 3.332

Review 2.  Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.

Authors:  P Molero; J A Ramos-Quiroga; R Martin-Santos; E Calvo-Sánchez; L Gutiérrez-Rojas; J J Meana
Journal:  CNS Drugs       Date:  2018-05       Impact factor: 5.749

Review 3.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

4.  The R-Stereoisomer of Ketamine as an Alternative for Ketamine for Treatment-resistant Major Depression.

Authors:  Kenji Hashimoto
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-04-24       Impact factor: 2.582

Review 5.  Ketamine enantiomers in the rapid and sustained antidepressant effects.

Authors:  John Muller; Sahana Pentyala; James Dilger; Srinivas Pentyala
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-10

Review 6.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

7.  Ketamine use among regular tobacco and alcohol users as revealed by respondent driven sampling in Taipei: prevalence, expectancy, and users' risky decision making.

Authors:  Wei J Chen; Te-Tien Ting; Chao-Ming Chang; Ying-Chun Liu; Chuan-Yu Chen
Journal:  J Food Drug Anal       Date:  2013-12       Impact factor: 6.079

Review 8.  Ketamine for chronic pain: risks and benefits.

Authors:  Marieke Niesters; Christian Martini; Albert Dahan
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

9.  Ketamine beyond anesthesia: Antidepressant effects and abuse potential.

Authors:  Keith A Trujillo; Sergio D Iñiguez
Journal:  Behav Brain Res       Date:  2020-07-31       Impact factor: 3.332

Review 10.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.